Zacks.com on MSN2d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
FiercePharma5d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
BioSpace5d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment
Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, ...
Monthly Prescribing Reference1d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of ...